Document is current
Any future updates will be listed below
-
Authors
Calvet, Laure
Lemiale, Virginie
Mokart, Djamel
Peter, Schellongowski
Peter, Pickkers
Demoule, Alexande
Mehta, Sangeeta
Kouatchet, Achille
Rello, Jordi
Bauer, Philippe
Martin-Loeches, Ignacio
Seguin, Amelie
Metaxa, Victoria
Bisbal, Magali
Azoulay, Elie
Darmon, Michael http://orcid.org/0000-0003-4198-8038
-
Funding
Funding for this research was provided by:
Ministère de l’Enseignement supérieur, de la Recherche et de l’Innovation (PHRC AOM 08235)
- License Information
-
More Information
Article History
Received: 23 January 2024
Accepted: 18 June 2024
First Online: 31 July 2024
Declarations
:
: Both studies included in this analysis had appropriate institutional review board approval, were conducted according to local legislation and in accordance with Declaration of Helsinki.Patients or Patients’ next of kin consent, or (according to IRB decision and country legislation) Patients or Patients’ next of kin information and informal agreement to participate, were obtained before inclusion.
: M. Darmon report having received consulting fees from Sanofi and Gilead-Kite, research support from Astute Medical and MSD, and speaker fees from MSD, Gilead-Kite and Astellas. Elie Azoulay has received fees for lectures from Gilead, Pfizer, Baxter and Alexion. His research group has been supported by Ablynx, Ficher & Payckle, Jazz Pharma, and MSD. The other authors declare having no conflict of interest related to this manuscript.
